Activist Investors Push for Seer Board Overhaul Amid 97% Stock Decline
Event summary
- The Radoff-JEC Group, owning 7.7% of Seer (NASDAQ: SEER), released a presentation urging shareholders to replace CEO Omid Farokhzad and two directors at the July 28 annual meeting.
- They cite a 97% stock decline since IPO, $103M in shares sold by Farokhzad, and alleged mismanagement including adoption of a poison pill.
- Proposed replacements include Howard Berman, Joshua Horowitz, and Luis Rinaldini, citing their biotech and governance expertise.
The big picture
This activist campaign highlights growing shareholder dissatisfaction with executive performance in the biotech sector, particularly around strategic failures and governance structures. The 97% stock decline underscores broader challenges in maintaining investor trust amid shifting market dynamics. The proposed replacements emphasize expertise in M&A and capital allocation, suggesting potential restructuring may be on the horizon.
What we're watching
- Governance Dynamics
- Whether the Radoff-JEC Group can secure enough votes to oust current leadership at Seer's July meeting.
- Strategic Review
- How a potential new board might approach a strategic review of Seer's operations and capital allocation.
- Leadership Impact
- The pace at which leadership changes could affect investor confidence and operational direction.
Related topics